Story perspectives

Pfizer's Updated COVID Vaccine Boosts Antibodies in Seniors

9/10/2025

31 7

Summary

Story summary

Pfizer and BioNTech's updated COVID-19 vaccine, Comirnaty, increased neutralizing antibodies fourfold in adults aged 65 and older and those with underlying conditions within 14 days.
A Phase III trial with 100 participants confirmed a consistent safety profile.
Nearly five billion doses have been administered globally, with FDA approval for high-risk groups.
Vaccine access varies by state, with some requiring prescriptions.
Common side effects include allergic reactions and fatigue.

1 of 1

Story summary

Pfizer and BioNTech's updated COVID-19 vaccine, Comirnaty, increased neutralizing antibodies fourfold in adults aged 65 and older and those with underlying conditions within 14 days.
A Phase III trial with 100 participants confirmed a consistent safety profile.
Nearly five billion doses have been administered globally, with FDA approval for high-risk groups.
Vaccine access varies by state, with some requiring prescriptions.
Common side effects include allergic reactions and fatigue.